Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2014 Sep;30(Suppl 1):202-4.
doi: 10.1007/s12288-013-0327-3. Epub 2014 Feb 9.

Autologous immune enhancement therapy in Philadelphia chromosome positive acute lymphoblastic leukemia

Revathi Raj  1 , M Deenadayalan  1 , G Vimal Kumar  1 , Vipin Khandelwal  1 , Karuna Sri  1 , Rajappa Senthilkumar  2 , Samuel J K Abraham  3 , Terunuma Hiroshi  4
Affiliations
Case Reports

Autologous immune enhancement therapy in Philadelphia chromosome positive acute lymphoblastic leukemia

Revathi Raj et al. Indian J Hematol Blood Transfus. 2014 Sep.

Abstract

Advances in current treatment regimens in childhood acute lymphoblastic leukemia (ALL) have resulted in cure rates of 75-80 %. Some molecular genetic abnormalities confer a poor prognosis. Of these, the chromosomal translocation t (9;22)-Philadelphia chromosome is associated with the worst outcome in childhood ALL. Optimal therapy for this variant of ALL includes chemotherapy as per high risk schedule, imatinib and early stem cell transplantation. We report here the successful natural killer cell-based autologous immune enhancement therapy along with chemotherapy and imatinib in a patient with Philadelphia chromosome positive ALL.

PubMed Disclaimer

References

    1. Aricò M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome–positive acute lymphoblastic leukemia. N Engl J Med. 2000;342:998–1006. doi: 10.1056/NEJM200004063421402. - DOI - PubMed
    1. Lake RA, Robinson BW. Immunotherapy and chemotherapy—a practical partnership. Nat Rev Cancer. 2005;5:397–405. doi: 10.1038/nrc1613. - DOI - PubMed
    1. Romagné F, Vivier E (2011) F1000 Med Reports 2011 3:9. doi:10.3410/M3-9 - PMC - PubMed
    1. Manjunath S, Ramanan G, Dedeepiya V, Terunuma H, Deng X, Baskar S, Senthilkumar R, Thamaraikannan P, Srinivasan T, Preethy S, Abraham S. Autologous immune enhancement therapy in recurrent ovarian cancer with metastases; 18 months follow-up—a case report. Case Rep Oncol. 2012 - PMC - PubMed
    1. Takada M, Terunuma H, Deng X, Dewan MZ, Saji S, Kuroi K, Yamamoto N, Toi M. Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach. Breast Cancer. 2010 - PubMed

Publication types